Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Keith Stewart

Showing results (31-40 of 215) with videos related to

Pageof 22
Sort By:
International Journal of Molecular Sciences|September 21, 2017
Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple MyelomaXiubao Chang, Qinqin Xu, Yuexian Hou, et al.
Leukemia Research|August 23, 2005
Analysis of PTEN deletions and mutations in multiple myelomaHong Chang, Xiao Ying Qi, Jaime Claudio, et al.
Leukemia & Lymphoma|August 5, 2004
Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysisHong Chang, Dan Li, Lihua Zhuang, et al.
Blood|March 3, 2007
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSuzanne Trudel, Zhi Hua Li, Jennifer Rauw, et al.
Blood|March 12, 2005
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myelomaHong Chang, A Keith Stewart, Xiao Ying Qi, et al.
Leukemia|April 23, 2004
Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 casesH Chang, S Samiee, D Li, et al.
British Journal of Haematology|September 26, 2015
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple MyelomaAllison Rosenthal, Shaji Kumar, Craig Hofmeister, et al.
Haematologica|May 16, 2015
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myelomaChang-Xin Shi, Klaus Martin Kortüm, Yuan Xiao Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistanceWilfrid Jaksic, Suzanne Trudel, Hong Chang, et al.
Blood|July 10, 2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaA Keith Stewart, Susanna Jacobus, Rafael Fonseca, et al.
Pageof 22

Showing results (31-40 of 215) with videos related to

Sort By:
Pageof 22
International Journal of Molecular Sciences|September 21, 2017
Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple MyelomaXiubao Chang, Qinqin Xu, Yuexian Hou, et al.
Leukemia Research|August 23, 2005
Analysis of PTEN deletions and mutations in multiple myelomaHong Chang, Xiao Ying Qi, Jaime Claudio, et al.
Leukemia & Lymphoma|August 5, 2004
Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysisHong Chang, Dan Li, Lihua Zhuang, et al.
Blood|March 3, 2007
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSuzanne Trudel, Zhi Hua Li, Jennifer Rauw, et al.
Blood|March 12, 2005
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myelomaHong Chang, A Keith Stewart, Xiao Ying Qi, et al.
Leukemia|April 23, 2004
Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 casesH Chang, S Samiee, D Li, et al.
British Journal of Haematology|September 26, 2015
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple MyelomaAllison Rosenthal, Shaji Kumar, Craig Hofmeister, et al.
Haematologica|May 16, 2015
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myelomaChang-Xin Shi, Klaus Martin Kortüm, Yuan Xiao Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistanceWilfrid Jaksic, Suzanne Trudel, Hong Chang, et al.
Blood|July 10, 2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaA Keith Stewart, Susanna Jacobus, Rafael Fonseca, et al.
Pageof 22